Joan Merrill to Antibodies, Antinuclear
                            
                            
                                This is a "connection" page, showing publications Joan Merrill has written about Antibodies, Antinuclear.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            1.492
         
        
        
     
 
    
        
        - 
            Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2022 08; 81(8):1143-1150.
            
            
                Score: 0.176
             
- 
            Immune Response to Enterococcus gallinarum in Lupus Patients Is Associated With a Subset of Lupus-Associated Autoantibodies. Front Immunol. 2021; 12:635072.
            
            
                Score: 0.166
             
- 
            Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype. J Allergy Clin Immunol. 2020 12; 146(6):1419-1433.
            
            
                Score: 0.155
             
- 
            Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care Res (Hoboken). 2019 07; 71(7):893-902.
            
            
                Score: 0.145
             
- 
            Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018 06; 77(6):883-889.
            
            
                Score: 0.133
             
- 
            Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity. Arthritis Rheumatol. 2016 10; 68(10):2492-502.
            
            
                Score: 0.120
             
- 
            Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production. Ann Rheum Dis. 2016 Nov; 75(11):2007-2013.
            
            
                Score: 0.114
             
- 
            Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Feb; 75(2):332-40.
            
            
                Score: 0.111
             
- 
            Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA. Ann Rheum Dis. 2016 Jan; 75(1):242-52.
            
            
                Score: 0.104
             
- 
            Low frequency of flares during pregnancy and post-partum in stable lupus patients. Arthritis Res Ther. 2020 03 19; 22(1):52.
            
            
                Score: 0.038
             
- 
            Kidney Outcomes and Risk Factors for Nephritis (Flare/De Novo) in a Multiethnic Cohort of Pregnant Patients with Lupus. Clin J Am Soc Nephrol. 2017 Jun 07; 12(6):940-946.
            
            
                Score: 0.031
             
- 
            Differential expression of the transcription factor ARID3a in lupus patient hematopoietic progenitor cells. J Immunol. 2015 Feb 01; 194(3):940-9.
            
            
                Score: 0.027
             
- 
            Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug; 64(8):2677-86.
            
            
                Score: 0.023
             
- 
            Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken). 2012 Jan; 64(1):132-7.
            
            
                Score: 0.022
             
- 
            A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 Dec; 63(12):3918-30.
            
            
                Score: 0.021
             
- 
            IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann Rheum Dis. 2012 Mar; 71(3):463-8.
            
            
                Score: 0.021
             
- 
            Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity. Lupus. 2011 Mar; 20(3):250-5.
            
            
                Score: 0.020
             
- 
            A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15; 61(9):1168-78.
            
            
                Score: 0.018
             
- 
            Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009 Sep 15; 61(9):1143-51.
            
            
                Score: 0.018
             
- 
            Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008; 10(5):R109.
            
            
                Score: 0.017
             
- 
            SR proteins are autoantigens in patients with systemic lupus erythematosus. Importance of phosphoepitopes. Arthritis Rheum. 2000 Aug; 43(8):1768-78.
            
            
                Score: 0.010